Positive data from Phase 2 SCOPE trial with SCIB1 | 18-Nov-2024 | 07:00 | RNS |
Result of Annual General Meeting | 25-Oct-2024 | 15:26 | RNS |
Holding(s) in Company | 24-Oct-2024 | 07:00 | RNS |
Scancell Appoints Dr Phil L’Huillier as CEO | 22-Oct-2024 | 07:00 | RNS |
Notice of AGM | 01-Oct-2024 | 07:00 | RNS |
Results Year Ended 30 April 2024 | 24-Sep-2024 | 07:00 | RNS |
Notice of Final Results | 18-Sep-2024 | 07:00 | RNS |
Strategic Partnership with PharmaJet | 17-Sep-2024 | 07:00 | RNS |
Scancell to attend upcoming conferences | 02-Sep-2024 | 07:00 | RNS |
Scancell Appoints Dr Nermeen Varawalla as CMO | 30-Jul-2024 | 07:17 | RNS |
Scancell Appoints Dr Nermeen Varawalla as CMO | 30-Jul-2024 | 07:00 | RNS |
Update from iSCIB1+ Clinical Advisory Meeting | 24-Jul-2024 | 07:00 | RNS |
Appointment of Dr Florian Reinaud to the Board | 10-Jul-2024 | 07:00 | RNS |
Extension of Convertible Loan Notes | 02-Jul-2024 | 07:00 | RNS |
Block Listing Return and Total Voting Rights | 01-Jul-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 14.50p |
Change Today | -0.50p |
% Change | -3.33 % |
52 Week High | 19.50 |
52 Week Low | 8.92 |
Volume | 601,540 |
Shares Issued | 927.98m |
Market Cap | £134.56m |
Beta | 0.49 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:29 | 100 @ 14.11p |
16:24 | 46 @ 14.00p |
16:23 | 50,285 @ 14.31p |
15:24 | 30,000 @ 14.50p |
15:23 | 50,000 @ 14.50p |
CFO | Sath Nirmalananthan |
CEO | Phil L'Huillier |
You are here: research